MIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.

“Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I’ve seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering.” says Herb Heyneker, who is based in the San Francisco Bay area. “I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. Sure, I am going to contribute anything in my powers to make that revolution happen.”

Dr. Jos Joore, Chief Business Officer of MIMETAS, comments: “We are extremely pleased to have Herb on board. Herb is one of the world’s biotech pioneers. He knows what it means to create paradigm shifts in life sciences. Moreover, his executive skills and impressive network will help to launch MIMETAS technology worldwide.

About Dr. Herbert L. Heyneker

After earning his PhD from Leiden University in Holland, Herbert Heyneker moved in 1975 to San Francisco to take a postdoc in Herbert Boyer’s UCSF lab where he was involved in gene splicing and somatostatin research. Soon afterward, he joined Genentech as one of the company’s first scientists. In 1984 he moved to Genencor, Genentech spinoff to become VP of R&D. He has held positions with Eos Biotechnology, ProtoGene Laboratories, GlycoGen and Genencor. He also served on the board of directors for GenPharm and Guava Technologies in the US and in the Netherlands, IntroGene (acquired by Crucell), Pharming, Pepscan and Prosensa. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.